Gebbia V, Carnaghi C. Metastatic clear cell sarcoma of the pancreas: A sporadic cancer. World J Clin Cases 2024; 12(18): 3291-3294 [DOI: 10.12998/wjcc.v12.i18.3291]
Corresponding Author of This Article
Vittorio Gebbia MD, PhD, Full Professor, Chair, Medical Oncology, Faculty of Medicine, University of Enna “Kore”, Enna 94100, Italy. vittorio.gebbia@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2024; 12(18): 3291-3294 Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3291
Metastatic clear cell sarcoma of the pancreas: A sporadic cancer
Vittorio Gebbia, Carlo Carnaghi
Vittorio Gebbia, Department of Medical Oncology, Faculty of Medicine, University of Enna “Kore”, Enna 94100, Italy
Vittorio Gebbia, Medical Oncology Unit, Cdc Torina, Palermo 90145, Italy
Carlo Carnaghi, Medical Oncology Unit, Humanitas Istituto Clinico Catanese, Misterbianco, Catania 95045, Italy
Author contributions: Gebbia V designed the overall concept and outline of the manuscript; Carnaghi C contributed to the discussion and design of the manuscript; Gebbia V and Carnaghi C contributed to the writing and editing of the manuscript and review of the literature.
Conflict-of-interest statement: All authors declare having no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Vittorio Gebbia MD, PhD, Full Professor, Chair, Medical Oncology, Faculty of Medicine, University of Enna “Kore”, Enna 94100, Italy. vittorio.gebbia@gmail.com
Received: February 27, 2024 Revised: April 14, 2024 Accepted: April 25, 2024 Published online: June 26, 2024 Processing time: 111 Days and 16.2 Hours
Abstract
Primary or secondary clear cell sarcoma of the pancreas is an exceedingly rare and aggressive disease. In addition to pathology, molecular analysis is pivotal in differential diagnosis, especially with malignant melanoma. A key aspect in identifying clear cell sarcoma is specific genetic alterations, notably the translocation of t(12;22) (q13;q13), a diagnostic hallmark of this sarcoma subtype, which is absent in malignant melanoma. Treatment of primary clear cell sarcoma of the pancreas is the same as that for adenocarcinoma.
Core Tip: Primary or secondary clear cell sarcoma of the pancreas is an exceedingly rare and aggressive disease. In addition to pathology, molecular analysis is pivotal in differential diagnosis, especially with malignant melanoma. A key aspect in identifying clear cell sarcoma is specific genetic alterations, notably the translocation of t(12;22) (q13;q13), a diagnostic hallmark of this sarcoma subtype that is absent in malignant melanoma. Treatment of primary clear cell sarcoma of the pancreas is the same as adenocarcinoma.
